Promising Alzheimer’s Treatment Fails In Trials
Intravenous immunoglobulin, or IVIG, had performed admirably in research being performed by doctors searching for an effective treatment of Alzheimer’s disease. In a phase II trial, IVIG appeared to show an ability to effectively stop the disease’s progression over a three year period. However, in the expanded phase III trial, patients showed no significant improvement as their cognitive and functional decline continued.
You can read more details at MedPage Today’s coverage. One other interesting tidbit is that the company sponsoring the research is not planning to completely pull the plug on IVIG research for Alzheimer’s. Though they believe it is no longer useful for mild to moderate Alzheimer’s patients, they did observe effectiveness in a small subgroup that gives them reason to continue their efforts, if only on a smaller scale.